# Study on the Safety and Effectiveness of UCB-NK Cell Infusion in the Treatment of Advanced Gastric Cancer and Gastroesophageal Cancer

> **NCT04385641** · NA · UNKNOWN · sponsor: **Shandong Golden Brick Biotechnology Co., Ltd.** · enrollment: 18 (estimated)

## Conditions studied

- Advanced Gastric Cancer
- Gastroesophageal Cancer

## Interventions

- **OTHER:** Cell infusion for Dose-finding (Group A)
- **OTHER:** Cell infusion for Extended research (Group B)

## Key facts

- **NCT ID:** NCT04385641
- **Lead sponsor:** Shandong Golden Brick Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-10-08
- **Primary completion:** 2021-10-08
- **Final completion:** 2022-10-08
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2020-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04385641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04385641, "Study on the Safety and Effectiveness of UCB-NK Cell Infusion in the Treatment of Advanced Gastric Cancer and Gastroesophageal Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04385641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*